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Table of Contents Category: Respiratory 
Key Points 
 
• Carotid body dysfunction is recognised as a cause of hypertension in a number of cardiorespiratory 
diseases states and has therefore been identified as a potential therapeutic target.  
 
• Purinergic transmission is an important element of the carotid body chemotransduction pathway.  
 
• We show that inhibition of ecto-5'-nucleotidase (CD73) in vitro reduces carotid body basal discharge 
and responses to hypoxia and mitochondrial inhibition.  
 
• Additionally, inhibition of ecto-5'-nucleotidase (CD73) in vivo decreased the hypoxic ventilatory 
response, reduced the hypoxia-induced heart rate elevation and exaggerated the blood pressure 
decrease in response to hypoxia.  
 
• Our data shows ecto-5'-nucleotidase to be a novel regulator of carotid body sensory function and 
therefore suggests this enzyme may offer a new target for reducing carotid body activity in selected 
cardiovascular diseases. 
 
Abstract 
 
Augmented sensory neuronal activity from the carotid body (CB) has emerged as a principal cause of 
hypertension in a number of cardiovascular related pathologies including obstructive sleep apnoea, 
heart failure and diabetes. Development of new targets and pharmacological treatment strategies 
aiming to reduce CB sensory activity may thus improve outcomes in these key patient cohorts. The 
current study tested whether ecto-5’-nucleotidase (CD73), an enzyme that generates adenosine, is 
functionally important in modifying CB sensory activity and cardiovascular respiratory responses to 
hypoxia. Inhibition of ecto-5’-nucleotidase by D,E-methylene ADP (AOPCP) in the whole CB 
  
 This article is protected by copyright. All rights reserved.  
preparation in vitro reduced basal discharge frequency by 76 ± 5% and reduced sensory activity 
throughout graded hypoxia. AOPCP also significantly attenuated elevations in sensory activity 
evoked by mitochondrial inhibition. These effects were mimicked by antagonism of adenosine 
receptors with 8-(p-sulfophenyl) theophylline. Infusion of AOPCP in vivo significantly decreased the 
hypoxic ventilatory response (Δ ̇E control 74±6%, Δ ̇E AOPCP 64±5%, P<0.05). AOPCP also 
modified cardiovascular responses to hypoxia, as evidenced by reduced elevations in heart rate and 
exaggerated changes in femoral vascular conductance and mean arterial blood pressure. Thus we 
identify ecto-5’-nucleotidase as a novel regulator of CB sensory activity. Future investigations are 
warranted to evaluate whether inhibition of ecto-5’-nucleotidase can effectively reduce CB activity in 
CB-mediated cardiovascular pathology.  
Abbreviations 
 
CB - carotid body. CD73 - ecto-5’-nucleotidase. AOPCP - D,E-methylene ADP. ENT - equilibrative 
nucleotide transporter. 8-SPT - 8-(p-sulfophenyl) theophylline. NBTI - nitrobenzylthioinosine. NO2- - 
nitrite. MABP – mean arterial blood pressure. FVC – femoral vascular conductance. HR – heart rate. 
 ̇E – minute ventilation. Vt – tidal volume. fR – respiratory frequency. HVR – hypoxic ventilatory 
response.  
 
 
Introduction 
 
Chronic carotid body (CB) over-activation has emerged as an important driver of hypertension in a 
number of cardiovascular related diseases including heart failure (HF), sleep disordered breathing 
(SDB) and diabetes (Ribeiro et al., 2013; Schultz et al., 2015; Del Rio et al., 2016; Prabhakar, 2016). 
Thus, development of novel treatment strategies that target the CB either pharmacologically or 
surgically may improve outcomes in these large patient populations. Indeed, some preliminary data 
suggests that bilateral CB resection decreases sympathetic outflow and improves exercise tolerance in 
human HF patients (Niewinski et al., 2017). In a small cohort of patients with drug resistant 
hypertension, unilateral CB resection caused a reduction in ambulatory blood pressure in 
approximately 50% of those studied (Narkiewicz et al., 2016). However, in view of the potential 
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safety concerns of bilateral resection, as indicated by a substantial reduction in O2 saturation during 
sleep (Niewinski et al., 2017), and the variable efficacy of unilateral resection (Narkiewicz et al., 
2016), pharmacological dampening of chemoreceptor activity may still offer a more viable treatment 
alternative. 
 
Carotid sinus nerve (CSN) discharge frequency, transmitted into the central nervous system (CNS), is 
the neuronal signal that promotes ventilatory and cardiovascular reflex responses originating from the 
CB, most notably in response to systemic hypoxia (Kumar & Prabhakar, 2012). Modification of CSN 
outflow is controlled by a number of important neurotransmitters and neuromodulators including 
ATP, acetylcholine, dopamine, serotonin, adrenaline and adenosine (Nurse, 2010) (McQueen & 
Ribeiro, 1986; Fitzgerald et al., 1999; Zhang et al., 2000; Conde et al., 2006; Conde et al., 2012; 
Hauton et al., 2013; Thompson et al., 2016). Adenosine is an established CB chemostimulant in both 
animals (Runold et al., 1990; Vandier et al., 1999; Conde et al., 2006; Xu et al., 2006; Conde et al., 
2012) and humans (Tubek et al., 2016). Better characterising the physiological relevance of adenosine 
and its generation and/or signalling pathways may provide useful information for identifying new 
potential targets for reducing CB chemoafferent activity. 
 
Synaptic adenosine may be generated following extracellular breakdown of ATP; a neurotransmitter 
tonically released from the CB type 1 cell (Piskuric & Nurse, 2013). Conversion of ATP to adenosine 
requires both membrane bound ectonucleoside triphosphate diphosphohydrolyase 1 (CD39) and ecto-
5’-nucleotidase (CD73) (Bianchi & Spychala, 2003). Expression of these two enzymes has been 
confirmed in extracts of the whole rat CB (Salman et al., 2016). Adenosine causes chemostimulation 
by either increasing type 1 cell excitability (via A2A and/or A2B receptors) (Conde et al., 2006; Xu et 
al., 2006; Conde et al., 2008; Livermore & Nurse, 2013) or by directly activating post-synaptic 
sensory fibres, (via A2A receptor stimulation) (Conde et al., 2006), both mechanisms acting to increase 
cAMP (Nunes et al., 2014; Holmes et al., 2015). Alternatively, it has been proposed that adenosine 
may be formed in the type 1 cell and then released directly into the synapse through the bidirectional 
equilibrative nucleotide transporter (ENT) (Cass et al., 1998). 
 
The current study tested whether pharmacological targeting of either ecto-5’-nucleotidase or ENT 
effectively reduces CSN discharge frequency in normoxic or hypoxic conditions. Furthermore, we 
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examined if ventilation, heart rate, blood pressure and vascular conductance responses to hypoxia 
were modified by targeting ecto-5’-nucleotidase in vivo. The data suggests that antagonism of ecto-5’-
nucleotidase but not ENT inhibits basal CSN frequency and blunts the response to hypoxia. Inhibition 
of ecto-5’-nucleotidase also attenuates ventilatory and cardiovascular responses to hypoxia. Thus, we 
propose ecto-5’-nucleotidase as a novel modulator of CB chemoafferent outflow.  
 
 
Methods 
 
Ethical approval 
The following procedures on animals were approved and carried out in line with the current Home 
Office (UK) and University of Birmingham guidelines on ethical use of animals. Adult male Wistar 
rats (n=32) were used for the study, supplied by Charles River Laboratories, Margate, UK. Animals 
were housed in individually ventilated cages in the Biomedical Services Unit at the University of 
Birmingham. Food and water was available ad libitum.  
 
Extracellular recordings of chemoafferent neurones 
Intact carotid bifurcations containing the CSN and CB were isolated from adult male Wistar rats 
(100–200 g) under inhalation anaesthesia (2-4% isoflurane in O2, 3L min-1), death by exsanguination. 
Following tissue procurement, animals were immediately killed by exsanguination. Connective tissue 
and surrounding structures were excised and the CSN was sectioned exposing nerve fibres and axons. 
To facilitate the extracellular neuronal recordings, the whole tissue was partially digested by 
incubation in enzyme Krebs solution (0.075 mg / ml collagenase type II, 0.0025 mg / ml dispase type 
I; Sigma Aldrich), at 37ºC, for 20–30 minutes. 
 
Extracellular recordings of chemoafferent activity were made from the cut end of the CSN as 
described previously (Holmes et al., 2014; Holmes et al., 2016). The superfusate PO2 was 
continuously measured using an O2 electrode (ISO2; World Precision Instruments) and O2 meter 
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(OXELP; World Precision Instruments). The PO2 and chemoafferent derived voltage were both 
recorded using a CED micro1401 (Cambridge Electronic Design) and visualised on a PC with Spike2 
(version 7.1) software (Cambridge Electronic Design). Chemoafferent voltage signal was sampled at 
15000Hz and the PO2 at 100Hz. Single fibres were used for analysis. Electrical activity originating 
from a single chemoafferent fibre was determined by its unique ‘wavemark’ signature based on 
frequency, shape and amplitude. 
 
Throughout experimentation, whole CBs were continuously superfused with a standard bicarbonate 
buffered Krebs solution containing, in mM: 115 NaCl, 4.5 KCl, 1.25 NaH2PO4, 5 Na2SO4, 
1.3 MgSO4, 24 NaHCO3, 2.4 CaCl2 and 11 D-glucose, 37ºC, pH 7.4. For normoxia/hyperoxia the 
superfusate PO2 was maintained throughout at a level that kept spontaneous chemodischarge between 
0.25 and 1.0Hz (Holmes et al., 2014). PCO2 was maintained at 40mmHg. For hypoxia, the 
superfusate PO2 was gradually reduced, at constant PCO2, until discharge was elevated above 10Hz. 
This was repeated in the presence of pharmacological agents used to target adenosinergic signalling 
pathways (AOPCP, 100µM (Conde & Monteiro, 2004; Holmes et al., 2015); 8-SPT, 300µM (Wyatt et 
al., 2007; Holmes et al., 2015) and NBTI, 10µM (Conde et al., 2012)) and again after drug washout. 
 
The single fibre chemoafferent discharge frequency was plotted against the superfusate PO2, and fitted 
to an exponential decay curve with offset, y = a + be-cx, where, y is the single fibre discharge 
frequency in Hz, x is the superfusate PO2 in mmHg, a is the discharge frequency as the PO2 tends to 
infinity (offset), b is the discharge frequency when the PO2 is 0 mmHg (minus the offset) and c is the 
exponential rate constant. In addition, for any given discharge frequency, the corresponding PO2 could 
be calculated using the inverse function of the exponential decay curve, x = -(Ln((y – a)/b))/c, where x 
is the PO2 in mmHg, y is the single fibre discharge frequency in Hz and a, b and c are constants as 
above. The PO2 at a frequency of 5Hz was used to quantify a PO2 shift in the hypoxic response curve. 
A value of 5Hz was chosen as it lies on the exponential region of the hypoxic response curve, but is 
not of a magnitude at which the discharge is likely to have started to diminish. 
 
To evaluate chemoafferent responses to mitochondrial inhibition, the rapidly reversible mitochondrial 
inhibitor nitrite (NO2-, 10mM) was used to induce moderate elevations in chemoafferent discharge 
(Holmes et al., 2016). Responses to NO2- were measured in control conditions, in the presence of 
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pharmacological agents targeting adenosinergic signalling pathways, as above, and again after drug 
washout.  
 
In vivo ventilatory and cardiovascular responses to hypoxia 
Adult male Wistar rats (Charles River Laboratories) were initially anaesthetised with 3-4% isoflurane 
in O2 at 3-4 L min-1 (Merial Animal Health Ltd). Following cannulation of the right jugular vein, 
isoflurane was removed and anaesthesia was maintained with i.v. Alfaxan® (Vétoquinol UK Ltd), at 
17-20 mg kg-1 h-1 with 0.1 ml boluses as necessary. Core body temperature was maintained at 37°C 
with a homeothermic heat pad system (Harvard Apparatus). 
 
The trachea was cannulated and a spirometer was attached to measure airflux; respiratory frequency 
(fR), tidal volume (Vt) and minute ventilation ( ̇E = fR x Vt) were derived from this. The tracheal 
cannula was connected to a system of rotameters in a gas proportioner frame (CP Instruments Co. 
Ltd) allowing variation of inspiratory gases. Animals breathed room air as the normoxic control. For 
hypoxia, animals inspired hypoxic gas mixture for 2 minute periods over the range of 20 to 8% O2. An 
arterial blood gas sample was taken at each inspired O2. The response to hypoxia was calculated as the 
mean of the last min of the exposure to hypoxia.  
 
Arterial Blood Pressure (ABP) was measured from the right brachial artery and heart rate (HR) was 
derived. Femoral blood flow (FBF; Transonic Systems Inc) was measured from the left femoral 
artery. Arterial blood samples were taken from the right femoral artery, utilising a looped cannula 
technique to reduce blood loss when sampling pure mixed arterial blood. Drug infusions of D,E-
methylene ADP (AOPCP; 160Pg kg-1, I.V. ) were given via the right femoral vein at a dose known to 
reduce vasodilation evoked by ATP infusion in similar in vivo studies (Skinner & Marshall, 1996). 
 
Analysis of data 
Values are expressed as mean ± standard error of mean unless otherwise stated. Statistical analysis 
was performed using i) a paired 2-tailed student’s t-test or ii) repeated measures one way Analysis of 
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Variance (ANOVA) with Bonferroni or Dunnett’s post hoc analysis where appropriate (StatView 
version 5 or GraphPad Prism version 6). Significance was taken as p<0.05. 
 
Results 
 
Ecto-5’-nucleotidase regulates peripheral chemoreceptor activity in normoxia and hypoxia.  
Inhibition of ecto-5’-nucleotidase using 100 PM AOPCP (Conde & Monteiro, 2004; Holmes et al., 
2015) reduced basal single fibre activity by 76 ± 5% (Figure 1A-C). AOPCP also significantly 
attenuated the CB chemoafferent response to hypoxia. A characteristic example of a single fibre 
hypoxic response is shown in Figure 1A & B and demonstrates a characteristic leftward shift in the 
hypoxia response curve caused by AOPCP. The inhibition was rapidly reversible and the original 
response to hypoxia was almost fully recovered after removal of the agent from the superfusate 
(Figure 1A & B). Mean chemoafferent discharge frequency was significantly depressed over a range 
of hypoxic superfusate PO2 values of 175 to 100mmHg (Figure 1D). Grouped paired measurements 
showed that AOPCP significantly decreased the superfusate PO2 required to elicit a discharge 
frequency of 5Hz by a mean value of approximately 30mmHg, consistent with blunted hypoxic 
sensitivity (Figure 1E). 
 
A similar reduction in basal frequency was observed in the presence of the adenosine receptor 
antagonist 8-(p-sulfophenyl) theophylline (8-SPT, 300 PM (Wyatt et al., 2007; Holmes et al., 2015)) 
(figure 2A& B). 8-SPT decreased chemoafferent activity at all PO2 levels but its inhibitory effect was 
enhanced during hypoxia (Figure 2A). In all fibres tested, addition of 8-SPT reduced CB hypoxic 
sensitivity, as evidenced by evoking a leftward shift in the chemoafferent hypoxic response curve, 
with a mean superfusate PO2 reduction at 5Hz measuring approximately 40mmHg (Figure 2B). To 
determine whether the neuromodulatory actions of adenosine are dependent on release through the 
ENT, additional hypoxic responses were performed in the presence of nitrobenzylthioinosine (NBTI; 
10PM, an inhibitor of ENT (Conde et al., 2012)). NBTI did not alter basal single fibre discharge 
frequency and had no effect on the chemoafferent response to hypoxia (Figure 2C & D). NBTI did not 
significantly alter the PO2 required to generate a 5Hz frequency and produced no change of 
chemoafferent activity throughout exposure of the CB to graded hypoxia (Figure 2C & D). 
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Ecto-5’-nucleotidase and adenosine mediate chemoreceptor responses to mitochondrial 
inhibitors.  
CB activation by hypoxia is commonly ascribed to be a direct consequence of depletion in 
mitochondrial energy metabolism (Buckler & Turner, 2013; Holmes et al., 2016). Thus AOPCP and 
8-SPT should have similar effects on CB responses to mitochondrial inhibitors. An example trace 
demonstrating the impact of 100PM AOPCP on the response to mitochondrial inhibition using NO2- is 
shown in Figure 3A. AOPCP almost completely abolished basal frequency and the response to NO2- 
(Figure 3B). The absolute elevation in chemoafferent activity evoked by NO2- (NO2- – basal) was 
significantly decreased in presence of AOPCP, measuring only approximately 0.4% of control (Figure 
3C). 8-SPT (300 PM) also significantly diminished frequency responses to NO2- (Figure 3D-E). The 
rise in discharge frequency elicited by NO2- in the presence of 8-SPT was reduced in each fibre 
studied, with the mean NO2--induced frequency elevation in the presence of 8-SPT measuring only 
approximately 20% of control (Figure 3D). Thus, AOPCP and 8-SPT are effective in attenuating CB 
responses to both hypoxia and mitochondrial inhibition. 
 
Ecto-5’-nucleotidase inhibition reduces hypoxic ventilatory sensitivity 
During normoxic breathing, AOPCP elevated baseline minute ventilation (control 187±10; AOPCP 
195±10 ml min-1, n=9), an effect that was due to an increase in tidal volume but not respiratory 
frequency (Figure 4A-C). Accordingly, under these normoxic conditions, AOPCP significantly 
reduced PaCO2 (control 45±1; AOPCP 39±1mmHg, P<0.05, paired 2-tailed student’s t-test, n=9), 
consistent with hyperventilation. Graded hypoxia increased minute ventilation, respiratory frequency 
and tidal volume (Figure 4A-C) and reduced PaCO2 (Figure 5A) in control and in the presence of 
AOPCP. However, AOPCP attenuated the magnitude of the hypoxic ventilatory response (HVR) (e.g. 
at 40mmHg PaO2; Δ ̇E control 74±6%, Δ ̇E AOPCP 64±5%, n=9) (Figure 4F). This attenuation in 
HVR was dependent on a reduction in the hypoxia-induced elevation in tidal volume but not 
respiratory frequency (Figure 4D-F). AOPCP also reduced the hypoxic exponential ventilatory rate 
constant (control 0.032±0.0044; AOPCP 0.022±0.003, n=9, P<0.01, paired t-test), signifying a 
decrease in hypoxic ventilatory sensitivity. Blood gas analysis revealed that the magnitude of the 
decrease in PaCO2 caused by hypoxia was also attenuated by AOPCP (Figure 5A & B). Collectively 
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these results suggest that whilst systemic pharmacological inhibition of ecto-5’-nucleotidase causes a 
baseline increase in ventilation, it also significantly attenuates the HVR. 
 
Ecto-5’-nucleotidase mediates cardiovascular responses to hypoxia 
Consistent with the baseline hyperventilation, AOPCP increased heart rate (control 441±12; AOPCP 
460±10bpm, n=9) and reduced femoral vascular conductance (control 0.016±0.001; AOPCP 
0.012±0.001 ml min-1 mmHg-1, n=8) during normoxic air breathing, but this did not cause an increase 
in mean arterial blood pressure (MABP) (Figure 6A-C). AOPCP attenuated the hypoxia induced rise 
in heart rate (HR) (e.g. at 40mmHg PaO2; ΔHR control 15±4%, ΔHR AOPCP 7±3%, n=9), enhanced 
the hypoxic increase in femoral vascular conductance (FVC) (e.g. at 40mmHg PaO2; ΔFVC control 
11±5 %, ΔFVC AOPCP 29±5 %, n=8) and exaggerated the fall in MABP (e.g. at 40mmHg PaO2; 
ΔMABP control -19±3%, ΔMABP AOPCP -26±4%, n=9) (Figure 6D-F). 
 
Discussion 
 
The present study identifies ecto-5’-nucleotidase (CD73) as a novel functional protein that contributes 
to CB and whole body cardiorespiratory responses to acute hypoxia. Inhibition of ecto-5’-nucleotidase 
activity dampens CB sensory neuronal discharge in vitro, both under basal conditions and during 
stimulation by hypoxia. In addition, pharmacological inhibition of ecto-5’-nucleotidase in vivo 
reduces the HVR and attenuates the hypoxia-induced rise in HR. Future investigations could evaluate 
whether targeting CB ecto-5’-nucleotidase activity may be effective in reducing persistent CB 
hyperactivity in selected pathologies.  
 
Ecto-5’-nucleotidase is a novel regulator of CB sensory discharge in normoxia and hypoxia 
Emerging evidence suggests that a chronic increase in CB sensory output in normoxia and hypoxia 
contributes significantly to hypertension and cardiac arrhythmia in patients and animal models of 
SDB, heart failure and diabetes (Ribeiro et al., 2013; Schultz et al., 2015; Del Rio et al., 2016; 
Prabhakar, 2016). This is due to the CB driving a chronic rise in sympathetic neuronal outflow to the 
vasculature and heart, thereby leading to persistent vasoconstriction and pro-arrhythmic cardiac 
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autonomic imbalance (Narkiewicz et al., 1998; Peng et al., 2003; Del Rio et al., 2016; Linz et al., 
2016). A number of recent small-scale clinical studies suggest that surgical uni- or bilateral CB 
ablation may be beneficial in reducing sympathetic outflow and arterial blood pressure in some 
patient cohorts (Narkiewicz et al., 2016; Niewinski et al., 2017). However, widespread use as a first-
line treatment option for CB mediated hypertension may be limited due to the potential safety 
concerns of complete loss of CB sensory activity, such as exaggerated O2 desaturation during sleep 
(Niewinski et al., 2017). This safety concern may be particularly relevant in patients with OSA who 
rely on CB sensory activity to cause arousal and recovery of airway patency. Furthermore, uni-lateral 
CB resection seems to confer a relatively short-term (up to 12 months) reduction in blood pressure 
and is effective in only about 50% of hypertensive patients (Narkiewicz et al., 2016). Thus, 
identifying new potential drug targets in the CB that can be targeted to reduce, but not abolish 
chemosensory activity, may offer a safer and more applicable treatment for this form of CB mediated 
hypertension.  
 
In this study we provide the first functional evidence that ecto-5’-nucleotidase mediates CB sensory 
discharge frequency in hypoxia. Ecto-5’-nucleotidase catalyses the formation of adenosine from 
AMP, following initial breakdown of ATP and ADP by CD39 (Bianchi & Spychala, 2003). In the CB, 
a significant synaptic ATP concentration is due to the tonic vesicular neurosecretion from the type 1 
cell (Zhang & Nurse, 2004) and also through ATP release from type 2 cells via pannexin-1 channels 
(Murali & Nurse, 2016). The attenuation of sensory discharge by inhibiting ecto-5’-nucleotidase is 
therefore most likely due to a reduction in adenosine formation. Indeed, we show that antagonism of 
adenosine receptors reduced normoxic and hypoxic CB sensory activity by an amount that was similar 
to inhibition of the ecto-5’-nucleotidase. Furthermore, antagonism of ecto-5’-nucleotidase and 
adenosine receptors both decrease the PO2 threshold required for CB activation during hypoxia, 
consistent with a comparable reduction in CB hypoxic sensitivity.  
 
Adenosine generated from ecto-5’-nucleotidase has the potential to modulate CB hypoxic sensitivity 
through activation of A2A and A2B receptors on the type 1 cell (Conde et al., 2006; Xu et al., 2006; 
Conde et al., 2008; Livermore & Nurse, 2013) or by stimulating the nerve ending upon binding to 
post synaptic A2A receptors (Conde et al., 2006). Both of these mechanisms are probable given that 
ecto-5’-nucleotidase will increase extracellular adenosine in the type 1 cell-chemoafferent synapse, 
thus having access to both pre-and post-synaptic receptors. Despite 8-SPT potentially also targeting 
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A1 receptors, a functional role is unlikely in our studies given the absence of A1 mRNA expression in 
the rat CB (Gauda, 2000; Kobayashi et al., 2000).  
 
Importantly, we also demonstrate that pharmacological antagonism of ecto-5’-nucleotidase reduces 
chemoafferent activity in hypoxia without completely abolishing it. Thus, effective targeting of ecto-
5’-nucleotidase would still allow for transmission of a definitive hypoxic neuronal signal into the 
CNS, albeit significantly reduced. Demonstration of significant ecto-5’-nucleotidase mRNA 
expression in the rat CB has been confirmed (Salman et al., 2016). However, the precise localisation 
of ecto-5’-nucleotidase and ectonucleoside triphosphate diphosphohydrolyase 1 (CD39) remains to be 
defined. Given the known co-localisation between ecto-5’-nucleotidase and A2A receptors in striatal 
neurones in the CNS (Augusto et al., 2013), we suggest that ecto-5’-nucleotidase in the CB is likely 
located similarly i.e. on type 1 cells and nerve endings.  
 
In contrast, inhibitory targeting of the ENT had no effect on the normoxic or hypoxic discharge 
frequency suggesting that insufficient quantities of adenosine are released through ENT in normoxia 
and hypoxia in order to impact directly on hypoxic neuronal discharge. This is consistent with earlier 
observations demonstrating that extracellular adenosine recovery in normoxia was independent on 
ENT activity (Conde & Monteiro, 2004; Conde et al., 2012). 
 
A direct up-regulation of ecto-5’-nucleotidase activity in the CB in chronic or chronic intermittent 
hypoxia remains to be verified. However, recent studies suggest that ATP and 5-HT can both augment 
ATP release from type 2 cells thereby amplifying synaptic ATP concentration (Murali & Nurse, 2016; 
Murali et al., 2017). Our data suggests that increased ecto-5’-nucleotidase activity driven by this 
increased availability of ATP would act to augment CB O2 sensitivity, and this may contribute to 
exaggerated chemoafferent responses observed in CH or CIH. 
 
Our data also shows that inhibition of ecto-5’-nucleotidase and adenosine receptors also attenuates 
sensory discharge frequency in response to mitochondrial inhibition. This is important not only 
because a run-down in mitochondrial energy metabolism is considered a necessary step in coupling 
hypoxia with type 1 cell stimulation (Duchen & Biscoe, 1992; Buckler & Turner, 2013; Holmes et al., 
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2016), but also in view of the evidence that chronic impairment of mitochondrial function is 
associated with the increase in CB sensory activity in animal models of OSA (Peng et al., 2003). 
Thus, our data supports the idea that functional inhibition of ecto-5’-nucleotidase inhibits basal and 
hypoxic discharge frequency and responses to stimuli relevant to CB pathology.  
 
Ecto-5’-nucleotidase reduces HVR and modifies cardiovascular responses to hypoxia 
Intravenous infusion of AOPCP to inhibit ecto-5’-nucleotidase in vivo caused an inhibition of HVR 
(Figure 4) and evoked a smaller reduction in PaCO2 during hypoxia (Figure 5), suggestive of a less 
marked hyperventilation. We also calculated that the hypoxic ventilatory exponential rate constant is 
depressed in the presence of AOPCP. These observations are in agreement with our in vitro data and 
suggest that AOPCP effectively blunts CB hypoxic sensitivity in vivo. Previous work has also show 
that 8-SPT (a compound that does not cross the blood brain barrier) also inhibits the acute phase of 
the HVR in rats (Lee et al., 2005), an action that our data implies is due to adenosine being important 
in establishing the CB sensitivity to hypoxia (Figure 2).  
 
AOPCP also reduced the HR response to hypoxia and exaggerated rise in FVC and fall in MABP. 
These data are consistent with a reduced elevation in sympathetic outflow to the heart and vasculature 
in hypoxia caused by ecto-5’-nucleotidase inhibition. In view of the positive correlation between CB 
chemodischarge and sympathetic outflow during hypoxic stimulation, the reduction in sympathetic 
activity is likely to be due to reduced CB stimulation. In addition, this could also be due to a lower 
level of hyperventilation and lung stretch receptor activation, again a consequence of blunted CB 
hypoxic chemodischarge and respiratory drive. If similar findings are validated in humans then 
pharmacological inhibition of CB ecto-5’-nucleotidase may offer a novel and important means of 
reducing cardiovascular sympathetic outflow in CB related pathology.  
 
That said, AOPCP also evoked a significant hyperventilation under normoxic conditions, as 
evidenced by a significant decrease in PaCO2. It also provoked a rise in baseline HR and reduced FVC 
in normoxia. Ecto-5’-nucleotidase is known to be expressed in brain regions where it regulates 
adenosine generation (Chu et al., 2014). Furthermore, A1 receptor activation depresses central 
respiratory drive (Montandon et al., 2007). Although speculative we therefore suggest that 
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hyperventilation in normoxic conditions is a consequence of a reduction in adenosine concentration in 
central respiratory brain regions following inhibition of cerebral ecto-5’-nucleotidase. This data raises 
the intriguing possibility that ecto-5’-nucleotidase may also have an important functional role in 
mediating central respiratory drive in normoxic conditions. These findings also suggest that selective 
targeting of the CB ecto-5’nucleotidase or development of nucleotidase inhibitors that do not cross the 
blood brain barrier could be necessary to selectively reduce CB sensory activity.  
 
Limitations 
The present studies were performed in rodents and validation of a functional role for CB ecto-
5’nucleotidase is necessary in humans. Our in vivo experiments were performed specifically using 
Alfaxan, an anaesthetic that improves preservation of cardiovascular reflexes. However, we cannot 
rule out that there would be some suppression of chemorecptor function, although we speculate that if 
this is the case then our estimates of reduction in HVR caused by ecto-5’nucleotidase may be an 
underestimate. Furthermore, our experiments used a pharmacological approach to probe the 
importance of ecto-5’-nucleotidase in CB function and HVR. We targeted ecto-5’-nucleotidase with 
AOPCP as this is known to be selective for membrane-bound ecto-5’-nucleotidase and has been used 
as such, previously, to distinguish the activities of membrane bound and cytosolic nucleotidases (Sala-
Newby et al., 2003). However, to validate our findings it would be interesting to perform similar 
experiments in mice deficient in CD73, ideally restricted to CB or tyrosine hydroxylase positive cells. 
Finally, in view of the present findings evaluation of expression levels of CB ecto-5’nucleotidase and 
contribution to CB sensory activity in diseases such as OSA, heart failure and diabetes is warranted.  
 
Conclusions 
Ecto-5’-nucleotidase (CD73) is a novel mediator of CB chemoafferent activity. Inhibition of ecto-5’-
nucleotidase reduces basal CB sensory neuronal activity and attenuates responses to hypoxia. 
Inhibition of ecto-5’-nucleotidase in vivo blunts HVR and modifies cardiovascular changes in 
hypoxia, including reduced HR elevation. Future studies will be important in order to assess whether 
ecto-5’-nucleotidase may be a feasible target for reducing CB activity and sympathetic outflow in CB 
related cardiovascular pathology. 
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Figure Legends 
 
Figure 1. Ecto-5’nucleotidase inhibition reduces CB sensory activity in hypoxia 
A Characteristic example of CB chemoafferent response to graded hypoxia (300–100mmHg PO2) 
recorded in the presence and absence of 100PM AOPCP. Overdrawn action potentials demonstrate 
the single fibre discrimination. B Hypoxic response curves for the corresponding fibre recorded in A. 
C Mean basal single fibre frequency ± AOPCP . D Mean frequency ± AOPCP during graded hypoxia. 
E PO2 values required to stimulate a discharge frequency of 5Hz during hypoxia ±AOPCP. For C-E 
** and *** denotes P<0.01 and P<0.001 AOPCP vs control, n=8 fibres, N=5 CB preparations.  
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Figure 2. Inhibition of adenosine receptors but not the equilibrative nucleotide 
transporter (ENT) blunts CB discharge frequency in hypoxia.  
A Mean single fibre frequency ± 8-SPT (300PM; adenosine receptor antagonist) during graded 
hypoxia. B PO2 values at 5Hz during hypoxia± 8-SPT. * and ** denotes P<0.05 and P<0.01 8-SPT vs 
control n=6 fibres, N=4 CB preparations. C Mean single fibre frequency ± NBTI (10PM; ENT 
antagonist) during graded hypoxia. D PO2 values at 5Hz during hypoxia ± NBTI. n=8 fibres, N=4 CB 
preparations. 
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Figure 3. Carotid body stimulation by mitochondrial inhibition is attenuated by 
antagonism of ecto-5’-nucleotidase and adenosine receptors.  
A Example recording of the CB sensory response to the mitochondrial inhibitor nitrite (NO2-; 10mM) 
in the presence and absence of AOPCP (100PM). Overdrawn action potentials demonstrate single 
fibre discrimination. B Mean discharge frequencies recorded under basal conditions and following 
addition of NO2-, ±AOPCP. C Frequency differences (NO2- – basal) for each fibre in the presence and 
absence of AOPCP. *** denotes P<0.001 AOPCP vs control, n=10 fibres, N=5 CB preparations. D 
Recording of the CB sensory response to NO2- in the presence and absence of 8-SPT (300PM). E 
Mean discharge frequencies recorded under basal conditions and following addition of NO2-, ± 8-SPT. 
E Frequency differences (NO2- – basal) for each fibre in the presence and absence of 8-SPT. 
**denotes P<0.01 8-SPT vs control, n=8 fibres, N=5 CB preparations. 
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Figure 4. Ventilatory responses to hypoxia are reduced by antagonism of ecto-5’-nucleotidase. 
A-C Respiratory frequency (fR), tidal volume (Vt) and minute ventilation ( ̇E) at baseline and in 
response to graded hypoxia, ±AOPCP (160µg.kg-1, I.V.). D-E % changes in fR, Vt and  ̇E at different 
calculated PaO2, compared to 100mmHg baseline, for control and during AOPCP infusion. For D-F *, 
** and *** denotes P<0.05, P<0.01 and P<0.001 AOPCP vs control, N=9. 
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Figure 5. Hypoxia induced fall in PaCO2 is blunted by inhibition of ecto-5’-nucleotidase. A 
Absolute changes in PaCO2 during graded hypoxia in the presence and absence of AOPCP. B 
Calculated reduction in PaCO2 per mmHg fall in PaO2, in the presence and absence of AOPCP. ** 
denotes, P<0.01, N=9. 
 
 
Figure 6. Cardiovascular responses to hypoxia are modified by inhibition of ecto-5’-
nucleotidase. A-C Mean arterial blood pressure (MABP), heart rate (HR) and femoral vascular 
conductance (FVC) during air breathing and in response to graded hypoxia, ±AOPCP (160Pg kg-1, 
I.V.). D-E % changes in MABP, HR and FVC at different calculated PaO2, compared to 100mmHg 
baseline, for control and AOPCP infusion. For D-F *and *** denotes P<0.05, and P<0.001 AOPCP vs 
control, N=9 (MABP and HR), N=8 FVC.  
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